Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Canakinumab Safety and Tolerability in Active SJIA
NCT01676948Phase 3Withdrawn
- Sponsor
- Novartis
- Start
- Jan 2013
- Primary completion
- Jan 2015
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
01
Overview
A Phase 3 trial of canakinumab in systemic juvenile idiopathic arthritis (SJIA), sponsored by Novartis. Planned start Jan 2013; status: withdrawn.
02
Drugs
canakinumab
03
Conditions
systemic juvenile idiopathic arthritis (SJIA)
Beyond the preview
Go deeper on NCT01676948.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01676948.